We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-32.2%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$11.8M
AUM Growth
-$6.52M
Cap. Flow
+$62.9K
Cap. Flow %
0.53%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$2.63M

Top Sells

Rank Stock Value
1
SURF
Surface Oncology, Inc. Common Stock
SURF
+$2.56M

Sector Composition

Rank Sector Weight
1 Communication Services 61.07%
2 Healthcare 38.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$130M
$5.84M 49.69%
1,145,492
– –
CHRS icon
2
Coherus Oncology
CHRS
$221M
$2.13M 18.08%
+568,408
New +$2.63M
SPRO icon
3
Spero Therapeutics
SPRO
$73.5M
$1.64M 13.93%
1,353,303
– –
SNAP icon
4
Snap
SNAP
$7.52B
$1.34M 11.38%
150,160
– –
SYBX
5
DELISTED
Synlogic
SYBX
$497K 4.23%
176,798
– –
NTLA icon
6
Intellia Therapeutics
NTLA
$1.56B
$316K 2.69%
10,000
– –
SURF
7
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-2,945,453
Closed -$2.56M

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q3 2023 Portfolio in Review

As of Q3 2023, Atlas Venture Associates IX held 7 positions worth $11.8M, down 36% from $18.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX's Q3 2023 filing shows 1 new and 1 closed positions. Its largest new stake was Coherus Oncology: 568,408 shares worth $2.13M. The largest sale was Surface Oncology, Inc. Common Stock, an estimated $2.56M.

By sector, the portfolio is most concentrated in Communication Services at 61% of assets, down from 67% a quarter earlier, followed by Healthcare.

  • Atlas Venture Associates IX's largest Q3 2023 buy was Coherus Oncology: 568,408 shares worth $2.13M.
  • Atlas Venture Associates IX fully exited Surface Oncology, Inc. Common Stock in Q3 2023, selling an estimated $2.56M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $11.8M portfolio in Q3 2023.
  • Atlas Venture Associates IX opened 1 new position and closed 1 in Q3 2023.
  • Atlas Venture Associates IX's portfolio value fell 36% quarter-over-quarter to $11.8M.

Based on Atlas Venture Associates IX's 13F filing for Q3 2023, filed 13 Nov 2023.